Latest Conference Articles

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

NCI Director Talks Response to COVID-19 Crisis, Focuses on Overcoming Disruptions in Cancer Care

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

Hudis Emphasizes Need for Cancer Research Funding During CFS® Keynote

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

Unlocking the Potential of Targeted Treatment Options for HCC

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

The Art of Choosing Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.

Hussain Discusses Progress of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

Mato Presents Sequencing Framework for Crowded CLL Landscape

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

Choosing the Optimal Frontline Approach for Low-Grade Follicular Lymphoma

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

BCMA-Targeting Drugs Take Center Stage in Myeloma

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Future of Immunotherapy in Melanoma to Focus on Overcoming Resistance, Personalizing Regimens

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Novel Triplets May Overcome Resistance to Targeted Therapy in BRAF+ Melanoma

The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.

Dr. Luke on the Importance of BRAF in Melanoma

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

XmAb18087 Shows Encouraging Preliminary Activity in NETs

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Novel Somatostatin Analog Shows Early Activity in Metastatic NETs, Irrespective of Primary Tumor Site

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Increased Lanreotride Autogel Dosing Shows Encouraging Antitumor Activity in Progressive Pancreatic, Midguts NETs

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Dr. Chauhan on the Role of Lutathera in NETs

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of ​Lutathera in neuroendocrine tumors.

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Telotristat/Lutathera Combo Could Improve Outcomes in Well-Differentiated NETs

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

Long-Term Toxicity Data Confirm the Tolerability of Lutathera in NETs

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Precision Medicine Picks up Pace Across Oncology

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.